Patients & Visitors

Cancer Services

To go directly to this page in future, please click here to add this page to your favourites.

Clinical Trials

Contact Us

Clinical Trials Unit
Haematology and Oncology Department
Royal United Hospital
Combe Park
BA1 3NG


Direct Line:
Fax:
01225 825096 / 821257
01225 821277

The office is open from 08.00am to 16.30pm Monday to Friday.

There are 6 Clinical Trials Nurses/Officers based in the office. Each nurse is responsible for their own Specific Cancer Site but they cover each other when unavailable.

Tumour Site Research Nurse
Haematology Christine Cox
Senior Clinical Trials Nurse
Tel: 01225 821105
Email: christinecox1@nhs.net
Tracy Ashburner
Clinical Trials Nurse
Tel: 01225 821105
Email: tracy.ashburner@nhs.net
Colorectal and Upper GI Claire Craige
Clinical Trials Nurse
Tel: 01225 825096
Email: claire.craige@nhs.net
Gynae Tom Tylee
Lead Clinical Trials Officer
Tel: 01225 821147
Email: thomas.tylee@nhs.net
Urology Rowan Appleby
Clinical Trials Nurse
Tel: 01225 826109
Email: rowan.appleby@nhs.net
Lung and Breast Tania Allen
Clinical Trials Nurse
Tel: 01225 826109
Email: tania.allen1@nhs.net
Radiotherapy Trials Tom Tylee
Clinical Trials Officer
Tel: 01225 821147
Email: thomas.tylee@nhs.net Carey Logan
Clinical Trials Officer
Tel: 01225 825096
Email: carey.logan@nhs.net
Genetics Carey Logan
Clinical Trials Officer
Tel: 01225 825096
Email: carey.logan@nhs.net Amy Gaunt
Clinical Trials Officer
Tel: 01225 826109
Email: amy.gaunt1@nhs.net

The Clinical Trials Nurses/Officer are supported by 3 other members of staff:

Samantha Curtis
Clinical Trials Co-ordinator
Tel: 01225 821178
Email: samantha.curtis@nhs.net
Michael Daly
Clinical Trials Administrator
Tel: 01225 825096
Email: michael.daly4@nhs.net
Jess White
Clinical Trials Assistant
Tel: 01225 821184
Email: jessicawhite2@nhs.net

back to top

What are Clinical Trials?

Clinical Trials are research studies into new types of medical care or combinations of medical care. Trials can be diverse. For instance, they may explore the biological, psychological or financial effects of a new treatment or they may focus on the prevention or diagnosis of an illness.

The development of clinical trials in cancer care is extremely important as a means of exploring and deciding on the most effective and efficient means of treating cancer. This is particularly important in the light of the multitude of new drugs and treatments which are constantly being developed.

The Clinical Trials Team co-ordinates and supports both national and in-house Oncology and Haematology clinical research studies for clinicians involved in cancer care at the Royal United Hospital NHS Trust.

Our team consists of 4 full time Clinical Trials Nurses, 2 part time Clinical Trials Nurse, 3 full time Clinical Trials Officers, 1 full time Clinical Trials Assistant, 1 full time Clinical Trials Co-ordinator and a Clinical Trials Administrator.

The team ensures that people who are involved in research studies have relevant information, support during and after treatment and the necessary follow-up appointments. We also ensure that Clinical Trials are organised and approved according to national regulations and guidelines and that the information collected in processed correctly to give accurate findings.

If you are eligible for a study that we are running, a member of the Clinical Trials Team will discuss it with you in detail. Participation is voluntary, and if you decide not to participate, this will not influence your treatment in any way.

We are situated in an office within the Oncology and Haematology Outpatients Department, RUH, North.

back to top

The Team

Each team member attends the Cancer Multi Disciplinary Team meetings that are applicable to their research tumour site at the RUH.

Extended members of the MDT

We link with and have access to all other RUH services and refer as appropriate.

back to top

Open Haematology Trials

These synopsis are open to change regularly. Please direct enquiries to the Clinical Trials Team on (01225) 825096.

  • AML 17: Adults or children with acute myeloid leukaemia or high risk myeodysplastic syndrome 17
  • FCLL: Genetic study of CLL and other lymphoproliferative disease.
  • InCiTe: Intracranial haemorrhage in thrombocytopenic haematology patients.
  • LI1: A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome.
  • MAJIC: A randomised study of best available therapy versus JAK inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide
  • RIALTO: A randomised investigation of alternative Ofatumumab-containing regimens in less fit patients with CLL.
  • PT 1– For patients under 59 years of age – Primary Thrombocythaemia.
  • UKAITPR - UK Adult Immune Thrombocytopenic Purpura (ITP) Registry
  • UKALL 14: A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia.
  • NSHLG: National Study of Hodgkin Lymphoma Genetics (NSHLG).
  • PACIFICO: Purine-alkylator combination in follicular lymphoma immuno-chemotherapy for older patients: a phase III comparison of the first line R-CVP VS R-FC lite.
  • Relapsed Mantle Cell Lymphoma - A parallel randomised Phase II Trial of CHOP Chemotherapy with or without Bortezomib in Relapsed Mantle Cell Lymphoma.
  • REMODL-B: A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Bortezomib.
  • PADIMAC: Phase II Study of Bortezomib, Adriamycin and Dexamethasone (PAD) Therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT
  • Brightlight: Do specialist cancer services for teenagers and young adults (TYA) add value? The 2012 TYA Cancer Cohort Study.
  • MDS BIO: Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis

back to top

Open Oncology Trials

These synopsis are open to change regularly. Please direct enquiries to the Clinical Trials Team on (01225) 825096.

  • Eribulin: Eribulin (HALAVEN®) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry.
  • Fast Forward: Randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer.
  • FH02: Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer.
  • Neo-Excel: Patients with ER positive postmenopausal early Breast Cancer.
  • OPTIMA: Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis.
  • Persephone: Duration of trastuzunab with chemotherapy in women with early breast cancer six months VS twelve.
  • Peruse: A multicentre, open-label, single arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2 positive advanced (metastatic or locally recurrent) breast cancer COSTAR – Radiotherapy Trial for patients with paratid tumours.
  • 6 weeks VS 12 weeks: Timing of surgery after preoperative radiotherapy 6 weeks VS 12 weeks.
  • ACORN: Avastin COloRectal Non-interventional study
  • FOXTROT: Fluoropyrimidine, Oxaliplatin & Targeted-Receptor pre-Operative Therapy for colon cancer.
  • NSCCG: National Study of Colorectal Cancer Genetics.
  • SCOT: A Study of Adjuvant Chemotherapy in Colorectal Cancer.
  • ST03: For patients with operable Oesophagogastric Adenocarcinoma.
  • STOPAH: Steroids or Pentoxifyylline for Alcoholic Hepatitis.
  • 6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours.
  • ICON 8: For women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer.
  • OSCAR-1: Avastin® Ovarian Non interventional study.
  • DE-ESCALATE: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma.
  • Head and Neck 5000: Non randomised epidemiology for patients with head and neck cancer.
  • NBT: National Brain Tumour Study.
  • ET: A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer.
  • I-START: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer.
  • LUX LUNG 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy.
  • Quartz: Quality of life after Radiotherapy and Steroids.
  • SMART: Surgical and large bore pleural procedures in Malignant Pleural Mesothelioma And Radiotherapy Trial.
  • COMET - 1: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100.
  • PATCH: A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer.
  • Radicals PR10: Patients with Prostate Cancer.
  • Stampede: Patients with Prostate Cancer.
  • SURTIME: Patients with metastatic renal cell carcinoma.
  • UKGPCS: Genetic study for Patients with Prostate Cancer.
  • UKGTCS: Genetic study for Patients with Testicular Cancer.
  • CUP ONE: Patients with carcinomas of unknown primary (CUP).
  • SCORAD III: Patients with metastatic spinal cord compression.

back to top

Useful Links

back to top